Immunome, Inc. $IMNM Shares Sold by EcoR1 Capital LLC

EcoR1 Capital LLC reduced its holdings in Immunome, Inc. (NASDAQ:IMNM) by 30.0% in the fourth quarter, HoldingsChannel reports. The firm owned 2,855,590 shares of the company’s stock after selling 1,223,825 shares during the period. Immunome makes up about 2.8% of EcoR1 Capital LLC’s investment portfolio, making the stock its 8th biggest holding. EcoR1 Capital LLC’s holdings in Immunome were worth $61,338,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd increased its holdings in Immunome by 6.1% in the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after purchasing an additional 631 shares in the last quarter. Creative Planning increased its holdings in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System increased its holdings in Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Up 3.5%

Shares of NASDAQ:IMNM opened at $18.53 on Thursday. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -7.79 and a beta of 2.04. Immunome, Inc. has a 12-month low of $7.96 and a 12-month high of $27.65. The business’s 50 day moving average is $21.56 and its 200 day moving average is $21.70.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.60) by $0.12. As a group, equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Insiders Place Their Bets

In other Immunome news, Director Jean Jacques Bienaime acquired 10,500 shares of the business’s stock in a transaction on Friday, June 5th. The shares were acquired at an average price of $19.45 per share, with a total value of $204,225.00. Following the completion of the transaction, the director owned 43,415 shares in the company, valued at approximately $844,421.75. This trade represents a 31.90% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the transaction, the insider directly owned 22,000 shares in the company, valued at approximately $476,080. This represents a 30.02% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 199,438 shares of company stock worth $4,058,464 in the last ninety days. Company insiders own 7.21% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on IMNM shares. Truist Financial boosted their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Barclays started coverage on Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 price objective for the company. Stephens decreased their price objective on Immunome from $33.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 4th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Finally, Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.